MagnetisMM-3: long-term update and outcomes of less frequent dosing of elranatamab in relapsed/refractory multiple myeloma
Searle, E. Prince, H. M. Bahlis, N. Rodriguez-Otero, P. Karlin, L. Akard, L. Varshavsky-Yanovsky, A. Nagai, Y. Vesole, D. Chu, M.
Searle, E.
Prince, H. M.
Bahlis, N.
Rodriguez-Otero, P.
Karlin, L.
Akard, L.
Varshavsky-Yanovsky, A.
Nagai, Y.
Vesole, D.
Chu, M.
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2025
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Searle E, Prince HM, Bahlis N, Rodriguez-Otero P, Karlin L, Akard L, et al. MagnetisMM-3: long-term update and outcomes of less frequent dosing of elranatamab in relapsed/refractory multiple myeloma. British journal of haematology. 2025 APR;206. PubMed PMID: WOS:001517858300048. English.